THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that the two previously filed shelf registration statements (S-3’s) are now effective. The first S-3, which became effective on January 7, 2010, registers stock that was issued to resolve previous creditor debt. The second S-3 is a universal shelf registration that allows the Company to issue up to $20 million worth of Repros preferred stock, common stock or warrants to acquire securities.
